Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSATRA: Tranylcypromine, ATRA, and Cytarabine in AML and MDS
NCT02717884Phase 2Unknown
- Start
- May 2015
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tranylcypromine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Primary endpoint: Maximum Tolerated Dose at 28 days. Status: unknown.
02
Drugs
tranylcypromine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02717884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02717884.